|
|
 |
|
Viewing report
|
|
|
|
Forecast Insight: Attention-Deficit Hyperactivity Disorder - Shire to stay on top despite drug safety fears and generic competition
Datamonitor, July 2009, Pages: 136
Driven primarily by continued uptake of Shires market leading ADHD drug, Adderall XR (amphetamine extended release), seven major market ADHD revenues grew strongly at a compound annual growth rate (200408) of 13.5% to reach almost $4.4 billion in 2008. Ongoing uptake of Shires Vyvanse (lisdexamfetamine), was also a key contributor to market growth between 2007 and 2008.
Scope
- This report gives a strategic analysis of the likely impact that recent events will have on the future ADHD market.
- Includes sales forecasts for the key ADHD brands and generics as well as pipeline agents in the seven major markets to 2018.
- Provides a global market snapshot by including sales analysis for leading ADHD brands outside the seven major markets.
- Key conclusions are supported by key opinion leader comment.
Highlights of this title
The April 2009 launch of generic competition in the US will cause sales of Shires leading ADHD product, Adderall XR, to decline sharply. However, Datamonitor maintains the expectation that Shire will remain the dominant player in the ADHD market over the forecast period due to the companys broad portfolio of products.
Intuniv (guanfacine hydrochloride) represents Shires first venture into the non-stimulant segment of the ADHD market. Datamonitor believes Shire will market Intuniv as a second-line treatment option, due to clinical data demonstrating inferior efficacy to stimulant treatments, putting it in direct competition with Strattera.
The publication of a US government-sponsored study reporting an association between ADHD treatments and sudden unexplained death among pediatrics will reignite the debate over the safety of ADHD drugs in children. The media coverage will cause some parents in the US to choose to discontinue or not begin stimulant therapy for their children.
Key reasons to purchase this title
- Understand when late-stage pipeline products will launch and what impact these will have on the market during the forecast period 2009 to 2018.
- Quantify the current size of the seven major markets and the trends in the rest of the world.
- Assess the impact of events, such as patent expiries and new product launches, on the future sales of key brand name ADHD products.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
U.S. Attention Deficit Hyperactivity Disorder (ADHD) Markets
Attention-Deficit Hyperactivity Disorder Market Forecast
US market size for attention deficit hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, by number of ADHD prescriptions and by dollar value of ADHD pharmaceutical sales; breakout of percent market share, number of prescrip
Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment
US market size for attention deficit / hyperactivity disorder drugs by number of diagnosed and treated ADHD patients, number of prescriptions and ADHD drug sales in US dollars for 1999 forecast to 2004, with breakdown of dollar sales, Rx numbers and
Pipeline Insight: ADHD - Shire Driving Diversity in ADHD
Commercial And Pipeline Insight: ADHD - Immature Adult Market Continues To Offer Greatest Commercial Potential
Adult ADHD - Strattera Grows Up
Attention Deficit Disorder with Hyperactivity Therapy Area Pipeline Report
CNS Drug Discoveries: Attention Deficit Hyperactivity Disorder Chapter
Stakeholder Insight: ADHD - Prescriber Attention Still Held by Short Acting Stimulant Drugs
Central Nervous System Attention Deficit Disorder with Hyperactivity
|
|
|
|
